https://www.selleckchem.com/pr....oducts/diphenyleneio
7% at week 24; all P 0.001 vs placebo). UACR remission rates at week 24 were 0.0%, 7.8%, 29.0%, and 28.1% in the placebo and apararenone 2.5mg, 5mg, and 10mg groups, respectively. eGFR tended to decrease and serum potassium tended to increase, but these events were not clinically significant. AE incidence increased with dose while ADR incidence did not. The UACR-lowering effect of apararenone administered once daily for 24weeks in patients with stage 2 DN was confirmed, and the 52-week administration was sa
Like
Comment
Share
